The strongest objective measurement of GLP-1 facial volume loss to date: 20 patients with CT/MRI imaging documenting median 9% midfacial volume loss (IQR 3-14%) and approximately 7% midfacial volume loss per 10 kg of weight loss, with median 11% loss in superficial fat compartments and median 7% in deep compartments
Unlike semaglutide , which targets only the GLP-1 receptor, or tirzepatide , which targets GLP-1 and GIP receptors, retatrutide activates all three metabolic receptors at once
[DOI] [PubMed] [Google Scholar] 48.Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., Nissen S.E., Pocock S., Poulter N.R., Ravn L.S., et al
Psychother Psychosom 64:141145 Kurhan F, Alp HH, Ik M, Atan YS (2022) The evaluation of thiol/disulfide homeostasis and oxidative DNA damage in patients with obsessive compulsive disorder
Data were extracted to examine descriptive statistics
Rather than addressing isolated markers, modern therapies aim to deliver holistic outcomesimproving blood sugar, supporting weight management, and reducing long-term complications
